Bladder Cancer - Results from #840

REVIEW UroToday

Field Cancerization Is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer. September 21, 2023

Bladder Sparing with Radiotherapy in Patients with Clinically Node-Positive Non Metastatic Bladder Cancer - Expert Commentary September 20, 2023

Secondary Bladder Cancer After Prostate Cancer Treatment: An Age-matched Comparison Between Radiation and Surgery. September 20, 2023

Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial). September 20, 2023

Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance. September 19, 2023

Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer. September 19, 2023

Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval. September 18, 2023

Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial. September 18, 2023

Does Chemo-Radiotherapy Improve Survival Outcomes vs. Radiotherapy Alone for High-Grade cT1 Urothelial Carcinoma of the Bladder? September 15, 2023

Patient Preferences for Adjuvant Treatment in Muscle-Invasive Urothelial Carcinoma: A Multi-Country Discrete Choice Experiment. September 15, 2023

Racial and Sex Differences in Tumor Genomics in Urothelial Carcinoma - Expert Commentary September 14, 2023

A Case-Only Genome-Wide Interaction Study of Smoking and Bladder Cancer Risk: Results from the COBLAnCE Cohort. September 14, 2023

Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy. September 14, 2023

Survival Prediction of Patients with Bladder Cancer after Cystectomy Based on Clinical, Radiomics, and Deep-Learning Descriptors. September 13, 2023

Cutaneous Ureterostomy Following Radical Cystectomy for Bladder Cancer: A Contemporary Series. September 13, 2023

Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. September 12, 2023

Adjuvant chemotherapy after radical cystectomy: Do all patients who need chemotherapy after surgery actually receive it? September 12, 2023

Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. September 12, 2023

pT1 Subclassification Predicts Progression-Free Survival in En Bloc Resection of Bladder Tumor Specimens. September 11, 2023

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin vs chemotherapy in patients with previously treated advanced urothelial carcinoma. September 11, 2023

Page 43 of 517